After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
I expect Allergan or another player to bid for SGYP soon.
Teva Pharmaceuticals (TEVA) stock is lower after successfully pricing in a debt offering for $15 billion worth of senior notes.
Cramer is a fan of Danaher and says to stick with CBRL Group.
Monday's headlines predicted a gloomy earnings season, Cramer says. What were they thinking?
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.